Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose aspirin for prevention of OHSS in IVF patients with polycystic ovary features
IRCT20210730052019N2Phase 2Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of aspirin in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: OHSS incidence and OHSS severity. Started Aug 2021; status: completed.
02
Drugs
aspirin
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on IRCT20210730052019N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210730052019N2.